Bristol-myers Company

Bristol-myers Squibb Compnay

Koko Sugawara

Masataka Konishi

Koji Tomita

Hiroshi Kawaguchi

Takeo Miyaki

Hideo Kamei

Masaru Ohbayashi

Toshikazu Oki

Masami Hatori

Michael R Kozlowski

Yosuke Sawada

Yuji Nishiyama

Disclosed are active compounds BU-4726G-A and BU-4726G-B which contain a quinone chromophore and hydroquinone chromophore, respectively. The compounds are produced by fermentation of Streptomyces exfoliatus AA4510. The compounds possess antimicrobial, and K.sub.ATP channel blocking activities.

Compounds produced by a strain of Streptomyces exfoliatus

New antibiotics designated BU-3292T A and B are provided which exhibit antimicrobial activity and also inhibit the growth of tumors in experimental animal systems. BU-3292T A is produced by fermentation of Elytrosporangium sp. nov. (ATCC 53784) while the BU-3292T B compound is obtained by oxidation of BU-3292T A.

BU-3292T antibiotics

A new antitumor antibiotic designated herein as BU-3862T is produced by fermentation of Streptomyces hygroscopicus ATCC 53709. BU-3862T and its diacetyl and dihydro derivatives inhibit the growth of tumors in experimental animals.

BU-3862T antitumor antibiotic

A novel antibiotic designated BU-4146T is produced by fermentation of Streptomyces amphibiosporus strain R310-104 (ATCC-53964). The antibiotic possesses both antifungal and antitumor activity.

BU-4146T antibiotic

The compound 3,7-dihydroxytropolone having the formula ##STR1## is produced by fermentation of Streptomyces tropolofaciens and is found to inhibit the growth of mammalian tumors.

Biologically pure culture of the microorganism Streptomycas

Process for producing 3,7-dihydroxytropolone and antitumor use thereof

A novel antibiotic complex designated BBM-2478 is produced by fermentation of an actinomycete strain J907-21 (ATCC 39417). The complex may be separated chromatographically into two bioactive components designated BBM-2478A and BBM-2478B. The BBM-2478A component displays both antibacterial and antitumor activity while the BBM-2478B component has antibacterial activity.

Process for preparing an antibiotic complex by culturing actinomyces

Disclosed is a process for preparation of the water-soluble peptide antibiotic designated Bu-2517 by fermentation of Empedobacter sp. strain G393-B445 (ATCC 31962).

Fermentation process for preparation of antibiotic Bu-2517

BBM-2478 Antibiotic complex

A novel water-soluble peptide designated herein as Bu-2517 is produced by fermentation of Empedobacter sp. strain G393-B445 (ATCC 31962). The antibiotic exists in a cyclic depsipeptide structure and contains the amino acids D-serine, D-proline, L-proline, D-threo-.beta.-hydroxyaspartic acid, L-threo-.beta.-hydroxyaspartic acid, L-arginine and trans-L-3-hydroxyproline and the residue of the C.sub.14 fatty acid, 3-hydroxytetradecanoic acid. The Bu-2517 antibiotic inhibits the growth of a variety of aerobic and anaerobic gram-positive bacteria.

Growing community of inventors

Saitama, Japan

Koko Sugawara